公开(公告)号：EP1197209A4

公开(公告)日：2005-01-05

申请号：EP00944383

申请日：2000-07-11

申请人： HISAMITSU PHARMACEUTICAL CO

发明人： TAKADA YASUNORI ,  TANAKA KOJI ,  IKEURA YASUHIRO

IPC分类号： A61K9/70 ,  A61K45/08 ,  A61K47/02 ,  A61K47/18 ,  A61P21/02 ,  A61P29/00 ,  A61K9/06 ,  A61K47/32

CPC分类号： A61K9/7053 ,  A61K9/0014 ,  A61K9/7061 ,  A61K9/7076 ,  A61K47/02 ,  A61K47/18 ,  A61K47/186 ,  Y10S514/887

摘要： Percutaneously absorbable preparations (preferably nonaqeuous ones, particularly matrix-type patches or ointments), containing salt-form acidic drugs and characterized by being improved in the percutaneous absorbability of the drugs by the incorporation of an addition salt of a basic substance therewith and by being lowly irritant to the skin; and a percutaneous absorption accelerator for salt-form acidic drugs, containing an addition salt of a basic substance.

公开(公告)号：EP1289964B1

公开(公告)日：2004-10-20

申请号：EP01933980.3

申请日：2001-05-17

申请人： F. HOFFMANN-LA ROCHE AG

发明人： MADERA, Ann, Marie ,  STABLER, Russell, Stephen ,  WEIKERT, Robert, James

IPC分类号： C07D241/08 ,  C07D267/10 ,  C07D243/08 ,  C07D265/10 ,  C07D267/22 ,  C07D267/06 ,  C07D409/12 ,  C07D417/12 ,  C07D403/12 ,  C07D413/12 ,  C07D409/06 ,  C07D413/06 ,  C07D401/12 ,  A61K31/395 ,  A61K31/495 ,  A61K31/55 ,  A61P1/06 ,  A61P11/06 ,  A61P13/06 ,  A61P21/02

CPC分类号： C07D207/27 ,  C07D211/76 ,  C07D223/10 ,  C07D225/02 ,  C07D239/10 ,  C07D241/08 ,  C07D243/04 ,  C07D243/08 ,  C07D265/10 ,  C07D267/06 ,  C07D267/10 ,  C07D267/22 ,  C07D279/06 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14 ,  C07D411/12 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14

公开(公告)号：EP1451158A1

公开(公告)日：2004-09-01

申请号：EP02782061.2

申请日：2002-11-01

申请人： AstraZeneca AB

发明人： CHAPDELAINE, Marc,AstraZeneca Wilmington ,  DAVENPORT, Timothy ,  HAEBERLEIN, Markus,AstraZeneca R & D Södertälje ,  HORCHLER, Carey,AstraZeneca Wilmington ,  MCCAULEY, John,AstraZeneca Wilmington ,  PIERSON, Edward,AstraZeneca Wilmington ,  SOHN, Daniel,AstraZeneca R & D Södertälje

IPC分类号： C07D215/42 ,  C07D215/48 ,  C07D215/233 ,  C07D207/14 ,  C07D241/04 ,  C07D243/08 ,  C07D265/30 ,  C07D401/14 ,  C07D413/14 ,  A61K31/496 ,  A61K31/551 ,  A61K31/5377 ,  A61P1/00 ,  A61P3/04 ,  A61P5/00 ,  A61P15/00 ,  A61P21/02 ,  A61P43/00

CPC分类号： C07D215/233 ,  C07D215/42 ,  C07D311/24 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D413/06 ,  C07D417/12 ,  Y02E60/324

摘要： Provided herein is a compound having the formula (I), (R2 is typically a tertiary nitrogen atom, being either alkyl-substituted or member of a heterocyclic ring; R7 is typically a monocyclic or bicyclic aromatic ring or a heterocyclic ring) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.

公开(公告)号：EP1418938A1

公开(公告)日：2004-05-19

申请号：EP02720315.7

申请日：2002-05-07

申请人： IMPERIAL COLLEGE INNOVATIONS LIMITED

发明人： LISK, G.,Imperial College of Science, Techn & Med ,  FORAN, P.ImperialCollege of Science, Tech. & Med ,  MEUNIER, F.Imperial College Science, Tech. & Med. ,  DOLLY, J.,Imperial College Science, Tech. & Med. ,  O'SULLIVAN, G.Imperial College Science Tech & Med

IPC分类号： A61K38/48 ,  A61K38/17 ,  A61K39/08 ,  A61P21/02 ,  A61P31/04

CPC分类号： A61K39/08 ,  A61K38/4893 ,  A61K2039/53 ,  Y02A50/469

摘要： A method for treating a patient with Botulinum toxin A (BoNT/A) or Botulinum toxin C1 (BoNT/C1) poisoning, wherein the patient is administered Botulinum toxin E (BoNT/E) or a polynucleotide encoding and capable of expressing BoNT/E, or a fragment derivable by cleavage of synaptosomal-associated polypeptide of 25 kDa (SNAP-25) or a variant thereof by BoNT/E (SNAP-25E) or a polynucleotide encoding and capable of expressing SNAP-25E. The patient may have botulism acquired naturally or accidentally, or may have been injected with BoNT/A or BoNT/C1 for medical purposes. A method for treating a patient in need of short duration inhibition of exocytosis in a cell of the patient, wherein the patient is administered BoNT/E or a polynucleotide encoding and capable of expressing BoNT/E, or a fragment derivable by cleavage of synaptosomal-associated polypeptide of 25 kDa (SNAP-25) or a variant thereof by BoNT/E (SNAP-25E) or a polynucleotide encoding and capable of expressing SNAP-25E and is not administered BoNT/A, B, C, F or G. The patient may be in need of inhibition of exocytosis of less than 14 days' duration.

公开(公告)号：EP1351968A4

公开(公告)日：2004-04-28

申请号：EP01271383

申请日：2001-12-20

申请人： BIONOMICS LTD

发明人： WALLACE ROBYN HEATHER ,  MULLEY JOHN CHARLES ,  BERKOVIC SAMUEL FRANK

IPC分类号： A01K67/027 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61K48/00 ,  A61P9/06 ,  A61P21/02 ,  A61P21/04 ,  A61P25/04 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/28 ,  A61P29/00 ,  A61P43/00 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12P21/08 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N37/00 ,  C07H21/04

CPC分类号： C07K14/705 ,  A01K2217/05 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/505 ,  C07K16/28

公开(公告)号：EP1362585A2

公开(公告)日：2003-11-19

申请号：EP02711756.3

申请日：2002-01-25

申请人： Osmotica Corp.

发明人： FAOUR, Joaquina ,  VERGEZ, Juan A.

IPC分类号： A61K31/00 ,  A61P29/00 ,  A61P21/02

CPC分类号： A61K9/2054 ,  A61K9/0004 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0095 ,  A61K9/02 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/4866 ,  A61K9/5084 ,  A61K45/06

摘要： The present invention provides a pharmaceutical composition and dosage form containing in combination a COX-II inhibitor and a muscle relaxant. The pharmaceutical composition is useful for the treatment of pain and pain related disorders and symptoms. The combination provides an improved therapeutic response as compared to either drug alone. The pharmaceutical composition can be included in any dosage form.

摘要翻译： 本发明提供了组合含有COX-II抑制剂和肌肉松弛剂的药物组合物和剂型。 药物组合物可用于治疗疼痛和疼痛相关的疾病和症状。 与单独使用药物相比，该组合提供了改善的治疗反应。 药物组合物可以包括在任何剂型中。

公开(公告)号：EP1246619A4

公开(公告)日：2003-05-02

申请号：EP00990246

申请日：2000-12-19

申请人： SMITHKLINE BEECHAM CORP

发明人： DHANAK DASHYANT ,  KNIGHT STEVEN DAVID ,  WARREN GREGORY LEE ,  JIN JIAN ,  WIDDOWSON KATHERINE L ,  KEENAN RICHARD MCCULLOCH

IPC分类号： A61K31/40 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5377 ,  A61P3/10 ,  A61P9/02 ,  A61P9/04 ,  A61P9/06 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P21/02 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P29/00 ,  A61P43/00 ,  C07D207/14 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  A61K31/34 ,  A61K31/415 ,  A61K31/47

CPC分类号： C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14

公开(公告)号：EP1131062A4

公开(公告)日：2002-07-03

申请号：EP99936010

申请日：1999-07-30

申请人： VETERINARY RES ASSOCIATES INC

发明人： KOMER GENE

IPC分类号： A61K9/08 ,  A61K31/05 ,  A61K31/14 ,  A61K31/167 ,  A61K31/225 ,  A61K31/4741 ,  A61K31/565 ,  A61K31/58 ,  A61K45/00 ,  A61K47/10 ,  A61K47/22 ,  A61K47/34 ,  A61P21/02 ,  A61P23/00 ,  A61P43/00

CPC分类号： A61K31/225 ,  A61K31/565 ,  A61K31/135 ,  A61K31/05 ,  A61K2300/00

摘要： The invention provides injectable formulations of propofol using N-methylpyrrolidone or 2-pyrrolidone as a solvent. Formulations of the invention are useful in all medical and veterinary indications when propofol is presently used. In addition, combinations of propofol and an appropriate toxin are useful for fast-acting, humane, veterinary euthanasia injectable compositions. N-methylpyrrolidone-propylene glycol formulations are inherently bacteriostatic, thereby eliminating one of the problems associated with currently available formulations.

公开(公告)号：EP1197209A1

公开(公告)日：2002-04-17

申请号：EP00944383.9

申请日：2000-07-11

申请人： HISAMITSU PHARMACEUTICAL CO. INC.

发明人： TAKADA, Yasunori, Hisamitsu Pharm. Co., Inc. ,  TANAKA, Koji, Hisamitsu Pharmac. Co., Inc. ,  IKEURA, Yasuhiro, Hisamitsu Pharmac. Co., Inc.

IPC分类号： A61K9/70 ,  A61K9/06 ,  A61K47/32 ,  A61K47/18 ,  A61K45/08 ,  A61P29/00 ,  A61P21/02

CPC分类号： A61K9/7053 ,  A61K9/0014 ,  A61K9/7061 ,  A61K9/7076 ,  A61K47/02 ,  A61K47/18 ,  A61K47/186 ,  Y10S514/887

摘要： Percutaneously absorbable preparations (preferably nonaqueous ones, particularly matrix-type patches or ointment), containing salt-form acidic drugs and characterized by being improved in the percutaneous absorbability of the drug by the incorporation of an addition salt of a basic substance therewith and by being lowly irritant to the skin; and a percutaneous absorption accelerator for salt-form acidic drugs, containing an addition salt of a basic substance.

摘要翻译： 包含盐形酸性药物的经皮吸收制剂（优选非水性制剂，特别是基质型贴剂或软膏剂），其特征在于通过加入碱性物质的加成盐，通过加入碱性物质的加成盐，提高药物的经皮吸收性 对皮肤的刺激性低; 以及含有碱性物质的加成盐的盐状酸性药物的经皮吸收促进剂。

公开(公告)号：EP0498941A3

公开(公告)日：1993-01-27

申请号：EP91119849

申请日：1991-11-21

申请人： BOC HEALTH CARE, INC.

发明人： CHENG, YEA-SHUN ,  KONTEATIS, ZENON D. ,  MACIELAG, MARK J. ,  PALMER, DAVID C.

IPC分类号： A61K38/00 ,  A61P21/02 ,  C07K5/02 ,  C07K5/08 ,  C07K5/087 ,  C07K5/09 ,  C07K5/097 ,  C07K5/10 ,  C07K7/06 ,  C07K5/04 ,  A61K37/02

CPC分类号： C07K5/0821 ,  A61K38/00 ,  C07K5/0202 ,  C07K5/0812 ,  C07K5/0815 ,  C07K5/0823